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Background: HIPEC with cisplatin in 
recurrent and advanced ovarian cancer 
(AOC) improves survival, but renal 
toxicity is common, even with renal 















carboplatin HIPEC for recurrent and AOC. 
Methods: Retrospective analysis of a 
cytoreductive surgery (CRS) /HIPEC registry 
was performed on recurrent and AOC 
patients treated between 2012-2018 with and 
without HIPEC. HIPEC with carboplatin 
(600-800 mg/mM2) was delivered for 90 
minutes at 41-42 C. Peritoneal Cancer Index 
(PCI), Completeness of Cytoreduction 
(CC)-score, nephrotoxicity by RIFLE score, 
thrombocytopenia, pancytopenia, length of 
stay (LOS), progression free survival (PFS), 
overall survival (OS), peritoneal relapse 
and all relapse events were collected and 
compared from the date of surgery. 
Results: A total of 34 recurrent and AOC 
patients had CRS, 21 treated with HIPEC. 
Mean PCI for CRS and CRS/HIPEC was 23 
and 22 respectively. 95% HIPEC and 100% 
no HIPEC had R0/R1/R2a. 9% developed 
>grade 1 AKI. Thrombocytopenia (platelet 
< 75K) occurred in 23% of HIPEC patients. 
LOS was 9.5 days for both groups. Post-CRS 
OS was 15 vs. 56 months for CRS vs. CRS/
HIPEC, p<0.01. There was no difference 










was 69% for CRS vs 19% for CRS/HIPEC, 
p<0.01. 
Conclusion: This data demonstrates that 
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to cisplatin without the nephrotoxicity. 







be attributable to peritoneal disease control 
and peritoneal relapse free survival may be 
a viable endpoint in future HIPEC clinical 
trials. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.031
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Background: MSLT established SLN 
management in extremity/trunk melanoma, 
demonstrating a 16% positive SLN (+SLN) 
rate and 14% positive non-SLN rate (+NSLN) 










Results of MSLT guide H&N melanoma but 
H&N only represented 13% of patients in 
MSLT II. This project explored the validity 
of observations reported in MSLT II in H&N 
melanoma.




with SLN injection and 108 SLN dissections 
were performed. Complication rates, T-stage, 
rates of +SLN, +NSLN in CLND were 
calculated, as well as death due to disease 
(DOD), progression free survival (PFS), along 
with rates of local (LR), nodal (LNR), and 
systemic (SR) recurrence. 
Results: T-stage was 41% IB, 23% IIA, 28% 
IIB, 8% IIC. Nerve complication was 4% 
for SLN and 11% for CLND. – SLN group 
survival is 93% compare to survival of 70% 
for +SLN group with median follow-up 
of 40 months. Rate of +SLN was 29% and 
+NSLN rate for CLND was 50%. Patients 
with positive SLN but did not undergo CLND 
(+SLNBx only) has surprisingly lower rate 
of LR, LNR, SR, and DOD when compared 
to patients with positive SLN who underwent 
CLND (CLND group). (Table 1.)
Conclusion: +SLN rate was 2-fold higher and 
+NSLN following CLND was 3-fold higher 
in H&N melanoma. Local regional recurrence 
rates were higher for CLND compared to 
SLNB+ only. These results support nodal 
Table 1.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) group demonstrates increased overall survival 
(OS), reduced rate of peritoneal relapse, and similar overall relapse rate when compared with non-
HIPEC group. Upfront HIPEC is associated with lower peritoneal relapse rate when compared with 
HIPEC performed after disease recurrence. 
GROUP # OSCRS 
months




ALL 34 34 - - - -
No HIPEC 13 20 73% 0% !" 87%
HIPEC 21 $ 42% 38% 19% 79%
HIPECrecurrent 9 $ 33% 15% 33% 92%
HIPECupfront 12 $ 23% 58% 8% 67%
